(Q35646362)

9 August 2017

title

Ciprofloxacin therapy of infections caused by Pseudomonas aeruginosa and other resistant bacteria (English)

1 reference

9 August 2017

main subject

Pseudomonas aeruginosa

1 reference

Eron LJ

1

1 reference

9 August 2017

Harvey L

series ordinal

2

1 reference

9 August 2017

Hixon DL

series ordinal

3

1 reference

9 August 2017

Poretz DM

series ordinal

4

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 August 1985

1 reference

Antimicrobial Agents and Chemotherapy

9 August 2017

published in

1 reference

9 August 2017

volume

28

1 reference

9 August 2017

issue

2

1 reference

9 August 2017

page(s)

308-310

1 reference

Moxalactam therapy of infections caused by cephalothin-resistant bacteria: influence of serum inhibitory activity on clinical response and acquisition of antibiotic resistance during therapy

9 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=180237

Clinical trial of piperacillin with acquisition of resistance by Pseudomonas and clinical relapse

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=180237

Use of ceftazidime in the therapy of serious infections, including those due to multiresistant organisms

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=180237

In vitro activities of norfloxacin and ciprofloxacin against Mycobacterium tuberculosis, M. avium complex, M. chelonei, M. fortuitum, and M. kansasii

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=180237

Ceftazidime in patients with pseudomonas infections

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=180237

In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=180237

Clinical experience with Moxalactam in the treatment of pseudomonal and nonpseudomonal infections

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=180237

Tobramycin sulfate: a summary of worldwide experience from clinical trials

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=180237

Piperacillin Therapy for Pseudomonas Infections

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=180237

A multiclinic randomized study of the comparative efficacy, safety and tolerance of imipenem/cilastatin and moxalactam

25 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/2939795

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1128/AAC.28.2.308

1 reference

9 August 2017

1 reference

9 August 2017

1 reference